See more : Mitsubishi Motors Corporation (MMTOF) Income Statement Analysis – Financial Results
Complete financial analysis of Vaxxinity, Inc. (VAXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaxxinity, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- RXR Acquisition Corp. (RXRA) Income Statement Analysis – Financial Results
- Candelaria Mining Corp. (CDELF) Income Statement Analysis – Financial Results
- PT Wilton Makmur indonesia Tbk. (SQMI.JK) Income Statement Analysis – Financial Results
- LungLife AI, Inc. (LLAI.L) Income Statement Analysis – Financial Results
- Auxico Resources Canada Inc. (AUAG.CN) Income Statement Analysis – Financial Results
Vaxxinity, Inc. (VAXX)
About Vaxxinity, Inc.
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 66.00K | 557.00K | 0.00 |
| Cost of Revenue | 2.23M | 1.68M | 1.94M | 52.00K | 107.00K |
| Gross Profit | -2.23M | -1.68M | -1.87M | 505.00K | -107.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -2,834.85% | 90.66% | 0.00% |
| Research & Development | 33.67M | 47.63M | 71.38M | 20.57M | 10.66M |
| General & Administrative | 22.39M | 28.35M | 51.83M | 12.22M | 3.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.39M | 28.35M | 51.83M | 12.22M | 3.01M |
| Other Expenses | 0.00 | 0.00 | -8.37M | -5.76M | -27.00K |
| Operating Expenses | 56.05M | 75.98M | 123.20M | 32.79M | 13.66M |
| Cost & Expenses | 58.29M | 75.98M | 125.14M | 32.84M | 13.66M |
| Interest Income | 2.09M | 1.26M | 9.00K | 1.00K | 435.00K |
| Interest Expense | 696.00K | 514.00K | 840.00K | 1.18M | 435.00K |
| Depreciation & Amortization | 2.23K | 1.68M | 1.10M | 717.00K | 107.00K |
| EBITDA | -56.05K | -74.30M | -135.23M | -31.57M | -13.58M |
| EBITDA Ratio | 0.00% | 0.00% | -187,824.24% | -6,701.26% | 0.00% |
| Operating Income | -58.29M | -75.98M | -125.08M | -32.28M | -13.66M |
| Operating Income Ratio | 0.00% | 0.00% | -189,507.58% | -5,795.69% | 0.00% |
| Total Other Income/Expenses | 58.23M | 757.00K | -12.10M | -7.68M | -502.00K |
| Income Before Tax | -56.93K | -75.22M | -137.18M | -39.96M | -14.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | -207,840.91% | -7,173.61% | 0.00% |
| Income Tax Expense | -56.93K | -12.00K | 840.00K | -4.58M | 56.00K |
| Net Income | -56.93K | -75.21M | -138.02M | -35.38M | -14.22M |
| Net Income Ratio | 0.00% | 0.00% | -209,113.64% | -6,351.35% | 0.00% |
| EPS | -0.45 | -0.60 | -1.10 | -0.28 | -0.11 |
| EPS Diluted | -0.45 | -0.60 | -1.10 | -0.28 | -0.11 |
| Weighted Avg Shares Out | 126.51K | 125.94M | 125.39M | 125.45M | 125.45M |
| Weighted Avg Shares Out (Dil) | 126.51K | 125.94M | 125.39M | 125.45M | 125.45M |
Congress makes $4.5 trading stocks in a day; Here's the biggest winners
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
Vaxxinity Issues Shareholder Letter
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024
Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Source: https://incomestatements.info
Category: Stock Reports